| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 08/27/2002 | US6441008 Benzamide derivatives as thrombin inhibitors |
| 08/27/2002 | US6440948 Thiophene A2A receptor agonists |
| 08/27/2002 | US6440939 Thrombin inhibitors |
| 08/27/2002 | US6440937 Competitive inhibitors of trypsin-like serin proteases, especially thrombin and kininogenases such as kallikrein; thrombin inhibitors, anticoagulants, and antiinflammatory agents |
| 08/27/2002 | US6440932 Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins |
| 08/27/2002 | US6440742 Recombinant AAV vector-based transduction system and use of same |
| 08/27/2002 | US6440417 Measuring concentration of therapeutic agent in blood or serum with high specificity; isolated monoclonal antibody produced by hybridoma cell line 9c10 having atcc accession number pta-3772 |
| 08/27/2002 | US6440414 Fibrolase and novel acting thrombolytic agents suitable for liquid frozen state or lyophilization storage; metallo-proteinase fibrinolytic agent of seq.id no: 1, zinc stabilizer, buffer and optionally a bulking agent |
| 08/27/2002 | US6440407 Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 (IL-3) multiple mutation polypeptides |
| 08/27/2002 | CA2125403C Novel tissue plasminogen activator variants |
| 08/22/2002 | WO2002064792A2 Molecules for disease detection and treatment |
| 08/22/2002 | WO2002064755A2 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 08/22/2002 | WO2002064748A2 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 08/22/2002 | WO2002064634A2 Human monoclonal antibodies to fc alpha receptor (cd89) |
| 08/22/2002 | WO2002064626A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 08/22/2002 | WO2002064606A1 Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
| 08/22/2002 | WO2002064590A2 Carboline derivatives |
| 08/22/2002 | WO2002064589A1 Laulimalide derivatives |
| 08/22/2002 | WO2002064586A2 Heterocyclic inhibitors of erk2 and uses thereof |
| 08/22/2002 | WO2002064584A1 Phthalayinone-piperidino-derivatives as pde4 inhibitors |
| 08/22/2002 | WO2002064576A1 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors |
| 08/22/2002 | WO2002064575A1 Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazolins and the utilization thereof as anticoagulant and antithrombotic agents |
| 08/22/2002 | WO2002064567A2 Substituted carboxamides as inhibitors of factor xa |
| 08/22/2002 | WO2002064565A1 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical |
| 08/22/2002 | WO2002064559A2 Thrombin inhibitors |
| 08/22/2002 | WO2002064552A1 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES |
| 08/22/2002 | WO2002064549A1 Ppar agonists |
| 08/22/2002 | WO2002064546A2 Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical |
| 08/22/2002 | WO2002064545A1 Acylated indanyl amines and their use as pharmaceuticals |
| 08/22/2002 | WO2002064211A1 Thrombin inhibitors |
| 08/22/2002 | WO2002064160A2 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 08/22/2002 | WO2002064148A2 Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders |
| 08/22/2002 | WO2002064146A1 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical |
| 08/22/2002 | WO2002064142A1 Farnesyl protein transferase inhibitor combinations with antiestrogen agents |
| 08/22/2002 | WO2002064140A1 Thrombin inhibitors |
| 08/22/2002 | WO2002064130A1 Proliferative activator receptor (ppar) compounds |
| 08/22/2002 | WO2002064083A2 Synthesis of 3-amino-thalidomide and its enantiomers |
| 08/22/2002 | WO2002064065A2 Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation |
| 08/22/2002 | WO2002064026A2 Treating pulmonary disorders with gaseous agent causing repletion of gsno |
| 08/22/2002 | WO2002063961A1 Composition and methods for modulation of vascular structure and/or function |
| 08/22/2002 | WO2002050125A3 Glycosaminoglycans derived from k5 polysaccharide having high antithrombin activity and process for their preparation |
| 08/22/2002 | WO2002045652A3 Tyrosine kinase inhibitors |
| 08/22/2002 | WO2002038167A3 Use of factor xiii for treating hemophilia b |
| 08/22/2002 | WO2002004412A3 Tyrosine derivatives as phosphatase inhibitors |
| 08/22/2002 | WO2002004008A3 Methods of therapy with thrombin derived peptides |
| 08/22/2002 | WO2001070214A3 The use of cocoa procyanidins combined with acetylsalicyclic acid as an anti-platelet therapy |
| 08/22/2002 | WO2000035423A9 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same |
| 08/22/2002 | WO2000023465A9 Methods and reagents for isolating biologically active peptides |
| 08/22/2002 | WO2000023092A9 Contulakin-g, analogs thereof and uses therefor |
| 08/22/2002 | US20020115858 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
| 08/22/2002 | US20020115856 Selective cyclooxygenase-2 (COX-2) inhibitors; for example, 1-(5-Methanesulfonyl-pyridin-2-yl)-7-methoxy-3-trifluoromethyl-4,5-dihydro -1H-benzo(g)indazole |
| 08/22/2002 | US20020115854 Thrombin or factor Xa inhibitors |
| 08/22/2002 | US20020115843 Nucleotide sequences for use in the treatment of viral diseases, hypertension and coagulation defects |
| 08/22/2002 | US20020115833 Glycoprotein for use in the treatment of kidney and blood disorders |
| 08/22/2002 | US20020115727 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| 08/22/2002 | US20020115716 Oral low dose butyrate compositions |
| 08/22/2002 | US20020115665 Contacting the calpain with an effective amount of an HIV protease inhibitor, |
| 08/22/2002 | US20020115627 Phosphatonin-related gene and methods of use thereof |
| 08/22/2002 | US20020115586 Contacting hematopoietic tissue with inhibitor(s) of nitric oxide synthase, to increase population of hematopoietic stem cells capable of undergoing normal hematopoiesis, differentiation and maturation |
| 08/22/2002 | US20020115152 Expression system for factor VIII |
| 08/22/2002 | US20020114848 Methods for regulating levels of zinc, cadmium and calcium in humans and for diagnosing, or screening for the risk of developing, diseases associated with abnormal levels of cadmium, zinc and calcium in body fluids and tissues |
| 08/22/2002 | US20020114796 Wound healing agents comprising fibrinogen, fibrin, thrombin, transglutaminase, and serpin protease inhibitor which doesn not inhibit collagenase and elastase in blood plasma |
| 08/22/2002 | US20020114791 Dehydration; freeze-drying; removing alcohol (sterol or cholesterol); loading with oligosaccharides to preserve; storage stability |
| 08/22/2002 | US20020112609 Cartridges useful in cleaning dialysis solutions |
| 08/22/2002 | CA2856986A1 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 08/22/2002 | CA2854685A1 Optimized messenger rna |
| 08/22/2002 | CA2438707A1 Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders |
| 08/22/2002 | CA2438551A1 Ppar agonists |
| 08/22/2002 | CA2438501A1 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 08/22/2002 | CA2438492A1 Proliferative activator receptor (ppar) compounds |
| 08/22/2002 | CA2438153A1 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 08/22/2002 | CA2436195A1 Laulimalide derivatives |
| 08/22/2002 | CA2436176A1 Thrombin inhibitors |
| 08/22/2002 | CA2436068A1 Thrombin inhibitors |
| 08/22/2002 | CA2433843A1 Molecules for disease detection and treatment |
| 08/22/2002 | CA2427112A1 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 08/22/2002 | CA2426535A1 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors |
| 08/21/2002 | EP1233065A1 G-CSF analog compositions and methods |
| 08/21/2002 | EP1232754A2 Use of cationic helix peptides for treatment of sepsis and for detection and removal of endotoxins |
| 08/21/2002 | EP1232750A1 Non-beta-oxidizable fatty acid analogues and their use for reduction of growth of cancer cells |
| 08/21/2002 | EP1232749A1 Non-beta-oxidizable fatty acid analogues and their uses for inhibition of oxidative modification of low density lipoprotein |
| 08/21/2002 | EP1232748A1 Substituted nitrobenzene derivatives as medicines and other useful uses thereof |
| 08/21/2002 | EP1232257A2 Modular transport systems for molecular substances and production and use thereof |
| 08/21/2002 | EP1232254A1 Process for the production of a reversibly inactive acidified plasmin composition |
| 08/21/2002 | EP1232252A1 Reversibly inactivated acidified plasmin |
| 08/21/2002 | EP1232251A1 Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| 08/21/2002 | EP1232180A1 Polypeptides derived from vitamin d nuclear receptor, and their uses in particular for screening vitamin d analogues |
| 08/21/2002 | EP1232174A1 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 08/21/2002 | EP1232172A1 Novel ribose compounds |
| 08/21/2002 | EP1232156A1 Novel 1,2,3]-triazolo 4,5-d]pyrimidine compounds |
| 08/21/2002 | EP1232150A1 Urea derivatives as anti-inflammatory agents |
| 08/21/2002 | EP1232144A2 Novel il-8 receptor antagonists |
| 08/21/2002 | EP1231940A1 Stable amorphous amifostine composition, and preparation thereof |
| 08/21/2002 | EP1231931A2 Methods of treating inflammatory bowel disease using cholera toxin b subunit |
| 08/21/2002 | EP1231913A2 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 08/21/2002 | EP1231908A2 Pharmaceutical composition comprising no or at least a no donor compound or another compound capable of releasing or inducing no formation in cells |
| 08/21/2002 | EP1231907A2 Dextrose and insulin fluid formulation for intravenous infusion |
| 08/21/2002 | EP0537160B1 Expression of recombinant hemoglobin in yeast |
| 08/21/2002 | CN1365356A Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect |
| 08/21/2002 | CN1365281A Metalloprotease inhibitors |